Company news

Lisata Therapeutics, Inc. news in 2026

Lisata Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences

November 5, 2026

Lisata Therapeutics Appoints Jeff Farrow to Board of Directors

October 14, 2026

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

October 5, 2026

Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement

September 17, 2026

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

August 4, 2026

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

June 10, 2026

Kuva Intends to Commence Tender Offer for Lisata Therapeutics by May 29, 2026

May 4, 2026

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

March 6, 2026

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

January 27, 2026

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

January 21, 2026

Decks in 2026